Article
Are Aspirin and Apixaban Sufficient to Prevent Immunothrombosis in COVID-19?
2020-12-29
Abstract excerpt
Severe COVID-19 disease is associated with respiratory and vascular injury and microvascular immunothrombosis mediated by complement activation, inflammatory lipid storm, platelet activation, platelet-leukocyte adhesion and activation of coagulation cascade. Amongst the inflammatory lipids, thromboxane A2 (TxA2) is a known key mediator of microvascular thrombosis. The levels of TxB2, a stable metabolite of TxA2 ar...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0d62f17c-dcde-5968-85aa-71ea87c3db3a
- DOI
- 10.2139/ssrn.3755292
